Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
PLYMOUTH, Minn., Jan. 28, 2016 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the Leerink Partners 5th Annual Global Healthcare Conference in New York, NY.
Entellus Medical’s management is scheduled to present on Thursday, February 11, 2016 at 12:00pm ET. Interested parties can access the live audio webcast at http://www.entellusmedical.com. An archived presentation will be available on the website for 30 days.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients. The Entellus Medical platform of products provides physicians with solutions to aid in the diagnosis and treatment of patients suffering from chronic sinusitis. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical's balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery ("FESS"). Patients treated with Entellus Medical's products in this trial in the ENT physician's office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. In addition to its XprESS line of products, Entellus Medical has recently introduced additional products designed to aid in the diagnosis, treatment and post-operative care of patients suffering from chronic sinusitis. For more information, please visit the Company's website at www.entellusmedical.com.
Carrie Mendivil 415-513-1283 [email protected]
